Aerosolized antibiotics in cystic fibrosis: Current and future trends

Expert Review of Respiratory Medicine

Volumn 2, Issue 4, 2008, Pages 479-487

  Fiel, Stanley B ^a,b  

^a MORRISTOWN MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Aerosolized antibiotic; Cystic fibrosis; Inhaled antibiotic; Inhaled tobramycin nebulization; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COLISTIMETHATE; DORNASE ALFA; GENTAMICIN; LIPOSOME; PIPERACILLIN; POLYMYXIN; TAUROLIDINE; TICARCILLIN; TOBRAMYCIN;

AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BRONCHIAL HYPERACTIVITY; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; DRUG TISSUE LEVEL; EQUIPMENT DESIGN; HOARSENESS; HUMAN; LUNG FIBROSIS; LUNG INFECTION; METERED DOSE INHALER; MINIMUM INHIBITORY CONCENTRATION; NEBULIZER; NEPHROTOXICITY; OTOTOXICITY; PARTICLE SIZE; POWDER INHALER; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; TINNITUS;

EID: 55149110275     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.4.479     Document Type: Review

References (51)

1. Cystic Fibrosis Foundation. Patient Registry: Annual Data Report, 2005. Cystic Fibrosis Foundation, Bethesda, MD, USA (2006).
2. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338(8769), 725-726 (1991).
3. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23(5), 330-335 (1997).
4. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999).
5. Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 106(6), E89 (2000).
6. di Sant'Agnese PEA, Andersen D. Celiac Syndrome. IV. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am. J. Dis. Child. 72, 17-61 (1946).
7. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 8(9), 1594-1604 (1995).
8. Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin. Respir. Crit. Care Med. 24(6), 717-726 (2003).
9. Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 22(3 Pt 2), S71-S79 (2002).
10. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis, Eur. Respir. J. 20(3), 658-664 (2002).
11. Murphy TD, Anbar RD, Lester LA et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. 38(4), 314-320 (2004).
12. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Grit. Care Med. 168(8), 918-951 (2003).
13. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 12(6), 428-432 (2006).
14. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur. Respir. J. 26(3), 458-461 (2005).
15. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 22(7), 840-847 (2004).
16. Burns JL, Van Dalfsen JM, Shawar RM et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5), 1190-1196 (1999).
17. Worlitzsch D, Tartan R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudamonas infections of cystic fibrosis patients. J. Clin. Invest. 109(3), 317-325 (2002).
18. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23(1), 146-158 (2004).
19. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 120(3 Suppl.), S94-S98 (2001).
20. Kuhn RJ. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 22(3 Pt 2), S80-S85 (2002).
21. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early, Pseudomonas colonisation in cystic fibrosis. Lancet 1 (8433), 865 (1985).
22. Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentanricin in cystic fibrosis and bronchiectasis. A pilot study. Am. J. Respir. Crit. Care Med. 160(5 Pt 1), 1711-1716 (1999).
23. Schaad UB, Wedgwood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J. Pediatr. 111(4), 599-605 (1987).
24. Gibson RL, Retsch-Bogart GZ, Oermann C et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41(7), 656-665 (2006).
25. Ledson MJ, Gallagher MJ, Robinson M et al. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. J. Aerosol. Med. 15(1), 51-57 (2002).
26. Estes L. Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin. Proc. 73(11), 1114-1122 (1998).
27. Touw DJ, Jacobs FA, Brimicombe RW et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 41(1), 184-187 (1997).
28. Alothman GA, Alsaadi MM, Ho BL et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 122(3), 930-934 (2002).
29. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55(5), 601-607 (2005).
30. LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120(3 Suppl.), S118-S123 (2001).
31. Westerman EM, Heijerman HG, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin. Drug Deliv. 4(2), 91-94 (2007).
32. Eisenberg J, Pepe M, Williams-Warren J et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 111(4), 955-962 (1997).
33. Mendelman PM, Smith AL, Levy J et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132(4), 761-765 (1985).
34. Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 34(3), 255-259 (1994).
35. Dopfer R, Brand P, Mullinger B et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J. Physiol. Pharmacol. 58(Suppl. 5 Pt 1), 141-154 (2007).
36. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 42(4), 307-313 (2007).
37. Fok TF, Monkman S, Dolovich M et al. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 21(5), 301-309 (1996).
38. Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin. Drug Deliv. 3(1), 71-86 (2006).
39. Retsch-Bogart GZ, Burns JL, Otto KL et al. A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol. 43(1), 47-58 (2008).
40. Le Brun PP, de Boer AH, Mannes GP et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur. J. Pharm. Biopharm. 54(1), 25-32 (2002).
41. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61(4), 859-868 (2008).
42. Halwani M, Mugabe C, Azghani AO et al. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J. Antimicrob. Chemother. 60(4), 760-769 (2007).
43. Shah SP, Misra A. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech. 5(4), e65 (2004).
44. Mugabe C, Azghani AO, Omri A. Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int. J. Pharm. 307(2), 244-250 (2006).
45. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N. Engl. J. Med. 331(10), 637-642 (1994).
46. Munck A, Bonacorsi S, Mariani-Kurkdjian P et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr. Pulmonol. 32(4), 288-292 (2001).
47. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55(6), 921-927 (2005).
48. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudamonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123(5), 1495-1502 (2003).
49. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366(9484), 463-471 (2005).
50. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 120(3 Suppl.), S107-S113 (2001).
51. Govan JR. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J. Cyst. Fibros. 1(Suppl. 2), 203-208 (2002).